$GMED · GLOBUS MEDICAL INC
Globus Medical filed its Q3 FY2026 10-Q. Net sales were $763.7M, down 0.7% from $769.0M a year earlier, while nine-month revenue grew 9.5% to $2.31B. Net income rose 19% YoY to $141.2M, with diluted EPS of $1.04 versus $0.88. Operating income climbed 29% to $177.6M as cost of sales, R&D, and SG&A all declined. The company repurchased $142.8M of stock in Q3.
- Q3 revenue declined 0.7% YoY to $763.7M, the first quarterly contraction in the period.
- Net income rose 19% to $141.2M, with diluted EPS of $1.04 versus $0.88.
- Operating income jumped 29% to $177.6M on lower cost of sales, R&D, and SG&A.
- Nine-month revenue grew 9.5% to $2.31B, aided by the Nevro merger.
- Company repurchased $142.8M of common stock in Q3, retiring 1.9M shares.
Extended-hours trading shows GMED at $78.50, down 3.70% from the $81.52 regular close, suggesting investors are weighing the revenue decline against the profit beat.
Globus delivered a strong profit beat on cost discipline even as revenue shrank, testing whether margin gains can sustain the stock without top-line growth.
Spine and musculoskeletal peers are contending with flat-to-declining procedural volumes; Globus is leaning on cost discipline and buybacks to offset stagnant top-line growth.
Revenue contraction of 0.7% YoY signals demand softness, while the Nevro integration and acquisition-related liabilities ($80.5M non-current) remain execution risks.